Immediate Impact
33 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Works of Cuncai Zhou being referenced
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.
2020
<p>Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy</p>
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Cuncai Zhou | 12 | 21 | 8 | 15 | 3 | 30 | |
| Friedrich Sinner | 7 | 28 | 3 | 16 | 3 | 35 | |
| Eric Assenat | 5 | 11 | 6 | 16 | 3 | 23 | |
| Brenda Hernandez | 5 | 24 | 3 | 15 | 2 | 42 | |
| Lei Huo | 3 | 13 | 6 | 6 | 4 | 36 | |
| Alba Kostandini | 3 | 16 | 6 | 7 | 2 | 29 | |
| T. Comont | 2 | 10 | 8 | 32 | 2 | 44 | |
| Chhagan Bihari Sharma | 16 | 5 | 4 | 5 | 3 | 27 | |
| Gaëlle Sickersen | 7 | 4 | 3 | 17 | 3 | 20 | |
| H. Mühlböck | 33 | 3 | 4 | 16 | 3 | 39 | |
| Saad Tahir | 3 | 3 | 10 | 23 | 4 | 29 |
All Works
Login with ORCID to disown or claim papers
Loading papers...